HighTide Biopharma Pty Ltd
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
25%
3 trials in Phase 3/4
36%
4 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Role: lead
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
Role: lead
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Role: lead
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Role: lead
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
Role: lead
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise
Role: lead
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Role: lead
A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Role: lead
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Role: lead
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
Role: lead
Study of HTD4010 in Healthy Volunteers
Role: lead
A Study of HTD1801 in Healthy Subjects
Role: lead
All 12 trials loaded